# The KN510713 Study in Combination With mFOLFIRINOX

> **NCT07114861** · PHASE1,PHASE2 · RECRUITING · sponsor: **New Cancer Cure-Bio Co.,Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

## Interventions

- **DRUG:** Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOX
- **DRUG:** Study drug: KN510 120mg/day + KN713 120mg/day, Combination Chemotherapy: mFOLFIRINOX

## Key facts

- **NCT ID:** NCT07114861
- **Lead sponsor:** New Cancer Cure-Bio Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-16
- **Primary completion:** 2028-09-22
- **Final completion:** 2028-10-22
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07114861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07114861, "The KN510713 Study in Combination With mFOLFIRINOX". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07114861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*